Summary
The distribution of125I-labelled recombinant mouse interferon-β (rMuIFN-β) in normal and glioma (203 glioma) bearing mice was studied by radioassay and macro-autoradiography at 15 and 30 min after a single intravenous injection. The level of rMuIFN-β in the spleen was about 20-fold higher than in serum. Concentrations higher than the serum level was detected in the lung, liver and kidney. The concentration of rMuIFN-β in the brain was 8% of the serum level and the concentration in the glioma 30 min after administration was about 10-fold higher than in normal mouse brain. Macro-autoradiographic study demonstrated a wide distribution range and selective uptake in glioma tissue. Furthermore, we found that mouse gliomas were sensitive to mouse IFN-β. Our findings demonstrate that in the mouse glioma model, intravenously administered interferon reaches the tumour.
Similar content being viewed by others
References
Aguet M (1980) High-affinity binding of125I-labeled mouse interferon to a specific cell surface receptor. Nature 284: 459–461
Alley MC, Scudiero DA, Monkes A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589–601
Armstrong JA (1981) Cytopathic effect inhibition assay for interferon: microculture plate assay. In: Pestka S (ed) Methods in enzymology, vol 78. Academic Press, New York, pp 381–387
Billiau A, De Somer P, Edy VG, De Clercq E, Heremans H (1979) Human fibroblast interferon for clinical trials: Pharmacokinetics and tolerability in experimental animals and humans. Antimicrob Agents Chemother 16: 56–63
Billiau A (1981) Perspective in cancer research: the clinical value of interferons as antitumor agents. Eur J Cancer Clin Oncol 17: 949–967
Billiau A, Heremans H, Ververken J, van Damme J, Carton H, de Somer P (1981) Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice. Arch Virol 68: 19–25
Bocci V (1981) Pharmacokinetic studies of interferons. Pharmac Ther 13: 421–440
Boëthius J, Blomgren H, Collins VP, Greitz T, Strander H (1983) The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme. Acta Neurochir (Wien) 68: 239–251
Cook AW, Carter WA, Nidzgorski F, Akhtar L (1983) Human brain tumor-derived cell lines: growth rate reduced by human fibroblast interferon. Science 219: 881–883
David GS, Reisfeld RA (1974) Protein iodination with solid state lactoperoxidase. Biochemistry 13: 1014–1021
Duff TA, Borden E, Bay J, Piepmeier J, Sielaff K (1986) Phase II trial of interferon-β for treatment of recurrent glioblastoma multiforme. J Neurosurg 64: 408–413
Geran RI, Congleton GF, Dudeck LE, Abbott BJ, Gargus JL (1974) A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs. Cancer Chemother Rep Part 2 4: 53–87
Groothuis DR, Fisher JM, Lapin G, Bigner DD, Vick NA (1982) Permeability of different experimental brain tumor models to horseradish peroxidase. J Neuropathol Exp Neurol 41: 164–185
Habif DV, Lipton R, Cantell K (1975) Interferon crosses blood-cerebrospinal fluid barrier in monkeys. Proc Soc Exp Biol Med 149: 287–289
Hanley DF, Wiranowska-Stewart M, Stewart WE II (1979) Pharmacology of interferons I. Pharmacologic distinctions between human leukocyte and fibroblast interferons. Int J Immunopharmac 1: 219–226
Heremans H, Billiau A, De Somer P (1980) Interferon in experimental viral infections in mice: Tissue interferon levels resulting from the virus infection and from exogenous interferon therapy. Infect Immuno 30: 513–522
Hirakawa K, Ueda S, Nakagawa Y, Suzuki K, Fukuma S, Kita M, Imanishi J, Kishida T (1983) Effect of human leukocyte interferon on malignant brain tumors. Cancer 51: 1976–1981
Kiuchi Y, Yonehara M, Okada K, Suzuki J, Kobayashi S (1984) The kinetics of interferon clearance in mice: comparison of mouse and human interferon. Exp Anim 33: 85–89
Kuroki M (1988) Antitumor effect of recombinant murine interferon-β against mouse brain tumors. J Jpn Sco Cancer Ther 23: 771–780
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685
Levin VA, Freeman-Dove M, Landahl HD (1975) Permeability characteristics of brain adjacent tumors in rats. Arch Neurol 32: 785–791
Levin VA, Shapiro WR, Clancy TP, Oliverio VT (1970) The uptake, distribution and antitumor activity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the murine glioma. Cancer Res 30: 2451–2455
Lowry DH, Rosenbrough MJ, Farr LA, Remdall RJ (1951) Protein measurements with Folin's reagent. J Biol Chem 193: 265–275
Mahaley MS Jr, Urso MB, Whaley RA, Williams TE, Guaspari A (1984) Interferon as adjuvant therapy with initial radiotherapy of patients with anaplastic gliomas. J Neurosurg 61: 1069–1071
Matsuda S, Utsumi J, Kawano G (1986) Purification and characterization of recombinant mouse interferon-β. J Interferon Res 6: 519–526
Nagai K, Arai T (1982) Interferon therapy for malignant brain tumors: present and future. Neurol Surg 10: 463–476
Nagai M, Arai T (1984) Clinical effect of interferon in malignant brain tumors. Neurosurg Rev 7: 55–64
Nagatuka S, Hanawa S, Honda T, Hasegawa M (1988) Quantitative analysis of whole body autoradiogram using a computer-assisted image analyzer. Xenobiotic Metabolism and Disposition 3: 121–135
Obbens EAMT, Feun LG, Leavens ME, Savaraj N, Stewart DJ, Gutterman JU (1985) Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies. J Neurooncol 3: 61–67
Priestman TJ (1980) Intitial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease. Lancet ii: 113–118
Reed DJ, Woodbury DM (1963) Kinetics of movement of iodine, sucrose, inulin and radio-iodinated serum albumin in the central nervous system and cerebrospinal fluid of the rat. J Physiol 169: 816–850
Salford LG, Strömblad L-G, Nordstrom C-H, Hornmark-Stenstam B, Brandt L, Brismar J, Brun A, Sjörgen HO, Flodgran P (1981) Intratumoral administration and interferon in malignant gliomas. Acta Neurochir (Wien) 56: 130–131
Satoh Y, Kasama K, Kajita A, Shimizu H (1984) Different pharmacokinetics between natural and recombinant human fibroblast interferon beta in rabbits. J Interferon Res 4: 411–422
Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR (1988) Evaluation of a soluble tetrazolium/formozan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48: 4827–4833
Stewart WE II, De Clercq E, De Somer P (1972) Recovery of cell-bound interferon. J Virol 10: 707–712
Tanaka T, Naruto M, Kawano G (1986) Production of recombinant mouse-interferon. J Interferon Res 6: 429–435
Treuner J, Dannecker G, Joester K-E, Hettinger A, Niethammer D (1981) Pharmacological aspects of clinical stage I/II: Trials with human beta interferon in children. J Interferon Res 3: 373–380
Ullberg S (1954) Studies on the distribution and fate of35 S-labelled benzylpenicillin in the body. Acta Radiol [Suppl] 118: 1–110
Yamazaki S, Kohase M, Tatsumi M, Onishi E, Morita C, Otaki S, Kohno S, Kono R (1982) Comparative kinetics of circulating interferon and physiological response in Cynomolgus monkeys given intramuscular and intravenous injections of interferons. In: Kono R, Vilcek J (eds) The clinical potentials of interferons. University of Tokyo Press, Tokyo, pp 281–293
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mihara, Y., Kuratsu, J., Takaki, S. et al. Distribution of mouse interferon-β in normal and brain tumour-bearing mice. Acta neurochir 109, 46–51 (1991). https://doi.org/10.1007/BF01405697
Issue Date:
DOI: https://doi.org/10.1007/BF01405697